Zacks: Brainstorm Cell Therapeutics Inc. (BCLI) Given $12.00 Average Target Price by Analysts
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $12.00 for the company and are anticipating that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Brainstorm Cell Therapeutics an industry rank of 102 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $9.00 price target on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th.
Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded down $0.09 on Friday, hitting $3.98. 49,878 shares of the stock traded hands, compared to its average volume of 134,298. Brainstorm Cell Therapeutics has a 12 month low of $2.07 and a 12 month high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the firm earned ($0.09) EPS. research analysts predict that Brainstorm Cell Therapeutics will post -0.37 EPS for the current fiscal year.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.